title: [Clinical Efficacy of Bleomycin, Cyclophosphamide, Vindesine, Ara-C and Dexamethasone for Treatment of Patients with Relapsed Refractory Diffuse Large B Cell Lymphoma].
abstract: OBJECTIVE
  To investigate the clinical efficacy of bleomycin, cyclophosphamide, vindesine, Ara-C and dexamethasone(BACOD) for treatment of patients with relapsed/refractory diffuse large B cell lymphoma.
  
  
  METHODS
  A total of 56 patients with relapsed/refractory diffuse large B cell lymphoma were divided into control group and treatment group. The control group were received the conventional BACOD treatment, and the treatment group received continuous venoclysis with BACOD. Clinical efficacy was observed and compared.
  
  
  RESULTS
  In control group, 6 patients achieved CR, 9 patients achieved PR, and their overall remission rate was 53.6%. In treatment group, 10 patients achieved CR, 12 patients achieved PR, and their overall remission rate was 78.6%. The overall remission rate of treatment group was significantly higher than that of control group (χ2=3.903, P<0.05). The incidence rates of nausea and vomiting, thrombocytopenia, abnormal liver function, fever and granulocytopenia were not significant difference (P>0.05) between the two groups.
  
  
  CONCLUSIONS
  The clinical efficacy of cyclophosphamide, vindesine and dexamethasone for treatment of patients with relapsed/refractory/diffuse large B cell lymphoma has been confirmed to be satisfactory, suggesting that the continuous venoclysis with BACOD can be apptied to the in clinical treatment.
authors.affiliation: Department of Oncology, Wuhan Municipal Puai Hospital, Wuhan 430033, Hubei Province, China. E-mail: 515554315@qq.com.
authors.forename: Hong
authors.initials: H
authors.lastname: Wan
authors.affiliation: Department of Oncology, Wuhan Municipal Puai Hospital, Wuhan 430033, Hubei Province, China.
authors.forename: Gang
authors.initials: G
authors.lastname: Feng
authors.affiliation: Department of Oncology, Wuhan Municipal Puai Hospital, Wuhan 430033, Hubei Province, China.
authors.forename: Xiao-Juan
authors.initials: XJ
authors.lastname: Wang
authors.affiliation: Department of Oncology, Wuhan Municipal Puai Hospital, Wuhan 430033, Hubei Province, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Wang
authors.affiliation: Department of Oncology, Wuhan Municipal Puai Hospital, Wuhan 430033, Hubei Province, China.
authors.forename: Xue-Lan
authors.initials: XL
authors.lastname: Huang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin; D003520:Cyclophosphamide; D003561:Cytarabine; D003907:Dexamethasone; D004317:Doxorubicin; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse; D012008:Recurrence; D016896:Treatment Outcome; D014750:Vincristine; D014751:Vindesine
chemical_list: D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D014751:Vindesine